Protecting hearts during chemotherapy in children
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial tests whether a medication can prevent heart damage in children and teens receiving chemotherapy. It is for patients aged 2 to 18 who can take oral medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A legal guardian must give permission for you to join the study
- You must be between 2 and 18 years old when first diagnosed
- You must be able to take pills by mouth
- You must not have a known allergy to heart-protective medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how chemotherapy and other cancer treatments affect the heart in children. It aims to find heart problems early so they can be treated quickly.
This trial uses detailed heart imaging (a special MRI scan) to see how chemotherapy may have affected your heart and to predict who could develop heart failure later. If you qualify, it may help your care team better monitor your heart health over time.
This study looks at what heart-related side effects happen in women with breast cancer who are planned to receive chemotherapy. It may help doctors better understand and monitor these risks during treatment.
This study tests whether a supervised exercise program can help protect the heart from damage caused by certain chemotherapy drugs (EC and docetaxel) used to treat early-stage breast cancer.
This study watches how chemotherapy and HER2-targeted drugs affect your heart during early-stage breast cancer treatment. Researchers use heart scans to catch any changes early and understand how to protect heart health.
This trial tests if a heart-protecting drug (dexrazoxane) can prevent heart damage in people getting chemotherapy for certain types of large B-cell lymphoma. It is for patients who already have heart risk factors or a history of heart failure.
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.